<DOC>
	<DOCNO>NCT00675025</DOCNO>
	<brief_summary>The purpose study determine safety donepezil hydrochloride ( Aricept ) child Down syndrome finished precede 10-week , double-blind study donepezil hydrochloride . Medical test drug safety conduct clinic visit .</brief_summary>
	<brief_title>Evaluating The Safety Of Donepezil Hydrochloride ( Aricept ) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week , Double-Blind , Placebo-Controlled Trial</brief_title>
	<detailed_description>All child study take donepezil hydrochloride day , come back clinic 8 , 24 42 week study begin . In clinic visit , clinical staff telephone child 's parent caregiver discuss drug safety observation possible change drug dose . At end study ( 42 week ) , psychological testing also give determine well child functioning .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Diagnosis Down syndrome ( establish study E2020A001220 ) . Completion study E2020A001219 ( also know A2501059 ) ongoing SAEs severe drug reaction . Weight le 20 kg . Clinically significant condition affect absorption , distribution metabolism study medication . No reliable parent caregiver , unwillingness inability parent caregiver fulfill requirement study . Females childbearing potential practicing effective mean birth control .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>